Ajanta Pharma Launches Met XL AMT 25 mg a triple FDC for Uncontrolled Hypertension with CAD

In a first move Ajanta pharma one of the leaders in the cardiology segment, has announced the launch of Met XL AMT 25 mg. It is a triple-drug combination for managing hypertension with coronary artery disease (CAD) uncontrolled on dual therapy.

Met XL AMT is the world’s first revolutionary FDC now available with flexible titration option without compromising efficacy, a triple fixed-dose combination of Metoprolol succinate (ER) 25 mg, Telmisartan 40 mg, and Amlodipine 5 mg. It is approved by the DCGI for treating essential hypertension with stable coronary artery disease in patients uncontrolled on dual FDC antihypertensive therapy.

According to the 2024 ESH/ESC guidelines, triple therapy is recommended when dual therapy fails. Beta-blockers (like metoprolol) are additionally recommended in the presence of compelling indications such as angina, post-myocardial infarction, systolic heart failure, or heart rate control¹.

In India, the burden of hypertension remains substantial, with nearly 1 in 3 adults affected. Hypertensive individuals are at nearly twice the risk of developing CAD compared to those without hypertension². Additionally, high blood pressure remains a leading contributor to stroke, particularly hemorrhagic stroke, which is more prevalent among Asian populations³.

Commenting on the launch, Mr. Pourus Vakil said “In India, where almost one-third of adults live with high blood pressure and many struggle to keep it under control, combination therapies are essential. Met XL AMT 25 is formulated to not only lower blood pressure effectively but also strengthen cardiovascular protection. Its launch underscores our dedication to elevating hypertension therapy and advancing heart health for patients across India.”

Mr. Chanchal Kumar Gop, Sr General Manager, Ajanta Pharma further added “Adherence to medication is vital for cardiovascular patients, as missed doses can increase the risk of heart attacks, strokes, and mortality. Non-adherence remains a significant challenge in managing cardiovascular health. Our triple fixed-dose combination (FDC) simplifies treatment, improving medication adherence and ensuring better compliance, ultimately reducing the risk of cardiovascular events and supporting long-term heart health.”

Ajanta Pharma is a specialty pharmaceutical formulation company having branded generic business in India and emerging markets, a generic business in US, Africa and middle east countries. Many of the company’s products are 1st to market and are leading in their sub-therapeutic segments.

References:

1) McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, Christodorescu RM, Daskalopoulou SS, Ferro CJ, Gerdts E, Hanssen H, Harris J, Lauder L, McManus RJ, Molloy GJ, Rahimi K, Regitz-Zagrosek V, Rossi GP, Sandset EC, Scheenaerts B, Staessen JA, Uchmanowicz I, Volterrani M, Touyz RM; ESC Scientific Document Group. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024 Oct 7;45(38):3912-4018. doi: 10.1093/eurheartj/ehae178. Erratum in: Eur Heart J. 2025 Apr 7;46(14):1300. doi: 10.1093/eurheartj/ehaf031. PMID: 39210715.

2) Ansuman Panigrahi, Soham Thakur, Alpana Mishra, Asis Kumar Ray, Basanta Kumar Behera, Smrutiranjan Nayak, Coronary artery disease, its’ socio-demographic and behavioral correlates in urban slum population of Bhubaneswar, India, Clinical Epidemiology and Global Health, Volume 28, 2024, 101666, ISSN 2213-3984, https://doi.org/10.1016/j.cegh.2024.101666

3) Biswas A, Singh SK, Singh RK. Linkages between Hypertension and Coronary Heart Disease in India: Evidence from India Human Development Survey-2 (2011-2012). Indian J Community Med. 2017 Oct-Dec;42(4):200-203. doi: 10.4103/ijcm.IJCM_168_16. PMID: 29184318; PMCID: PMC5682717.